Hainan Pilot Medical Tourism Zone
The southern part of the zone will feature health care centers for the elderly, patients with chronic disease and those in poor health, while the northern part will focus on medical treatment and research.
The State Council decided to suspend the implementation of Article 11, Item 2 of the Regulations on Supervision and Management of Medical Devices in the Boao Lecheng International Medical Tourism Advance Zone in Hainan to support the development of Hainan's international medical tourism industry.
According to the decision, if certain medical equipment not legally available in China is urgently needed in the early zone, the Hainan provincial government may authorize its importation, but such equipment must be used in designated hospitals.
The State Council urged the State Drug Administration, the Hainan provincial government and other relevant departments to develop specific regulations on the conditions and procedures for the approval of imported medical equipment.
Leveraging the benefits of Hainan's free trade port policy, the Boao Lecheng International Medical Tourism Advance Zone in Hainan will bring more international medical technology, products and equipment to China and develop medical beauty as a major growth driver for the advance zone. Since the State Council approved the establishment of Boao Lecheng in 2013, the zone has undergone a major transformation. To date, the Advance Zone has introduced more than 100 innovative drugs and medical devices from overseas.
The zone is the only area in China that enjoys nine preferential policies, including special permission to import medical technology, medical equipment and pharmaceuticals. These policies allow medical institutions in the zone to import and use much-needed drugs and equipment from overseas that have not yet been approved by China's top drug agency. Medical beauty is one of the special areas of Boao Lecheng and a key part of Hainan's development of health tourism. Next year, 20 medical institutions are expected to enter Boao Lecheng, including a number of specialized medical beauty institutions.
Allergan, a subsidiary of U.S. pharmaceutical company AbbVie, announced on July 2 that its medical aesthetic product Volux has begun collecting clinical data in Boao Lecheng. The product, which entered the Pilot Zone on Dec. 29th, is the first cosmetic surgery product approved in Lecheng.
"The reason we are bringing our medical aesthetic products to the Early Bird Zone is that we see a constant surge in demand. Every year, 600,000 Chinese people travel abroad for medical treatment, and 20 percent of them are seeking medical aesthetic services. We want Chinese residents to have access to international standard medical products without leaving the country."
The healthcare sector is a key industry for Hainan, and it is a priority industry for the construction of Hainan's free trade port. Specifically, medical aesthetics is of great importance due to the consumer nature of the port. Hospitals here include those affiliated with the Shanghai Jiao Tong University School of Medicine, which will be involved in the collection of clinical data, and through patient follow-up, data collection and analysis, the safety and effectiveness of the products can be assessed. The hospital will continue to build a platform for the landing of global advanced products, technologies and devices, conduct clinical trials, promote international cooperation and expand the scope and number of advanced drugs and devices in China by virtue of its status, ecology and policies.
©2022 - Boao Lecheng Private Equity Investment 版权所有